LumiraDx Limited

Good day, everyone. Thank you for standing by, and welcome to the Lumira DEX Third Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the Q&A, you will need to press star 1 on your telephone. If you require any further assistance, please press star 0. I will now hand the conference over to Colleen McMillan, Vice President of Communications Thank you. Please go ahead.

Hello, everyone. We'd like to welcome you to today's call to discuss Lumiere DX's third quarter financial results issued earlier this morning. With us are Lumiere DX's chairman and CEO, Ron Zwanziger, Chief Financial Officer, Dorian LeBlanc, and Chief Product Officer, Pooja Patek. The press release announcing third quarter results is posted on the Investor Relations section online. of the company's website at LumiereDx.com. Before we begin, I would like to caution listeners that any statements we make today, other than historical facts, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please be aware that all such forward-looking statements involve risk and uncertainties, such as those detailed in our proxy statement and prospectus filed with the SEC on September 10, 2021, and other filings with the SEC. Any forward-looking statements that we make must be considered in light of these factors. Actual results may vary materially. Also, during the course of today's call, we may refer to certain non-IFRS financial measures. There is a reconciliation schedule showing the IFRS versus non-IFRS results currently available, and our press release issued earlier today, which can be found on our website at LumiraDX.com. I will now turn the call over to Ron Wanziger for opening remarks. We will then provide Q3 financial and business updates before answering questions. Ron?

Thanks, Colleen, and thank you all for joining our call today. We've been working to build LumiraDX for seven years now with a vision for of transforming community-based care by providing fast, accurate, and comprehensive diagnostic information to healthcare providers at the point of need. Our next-generation diagnostic testing solution is designed to be affordable and accessible for every individual around the world. COVID exposed a further need for point-of-care testing with lab-comparable results. In minutes, our microfluidic technology and platform have proven to meet the market needs for fast, high sensitivity convenient and connected diagnostic test results. We have successfully gone into the market with customers and partners, including CVS, the UK National Health Service, the Italian Health Systems, and the Bill and Melinda Gates Foundation. Much of our growth this year has been driven by delivering rapid COVID testing in health systems, emergency rooms, retail pharmacy chains, and other community settings. The numbers we've posted today demonstrate the beginning of the utility of the platform and its tremendous growth potential from 139 million revenues for the first 2020 year as a whole to 109 million just this quarter and 303 million in revenues for the first nine months of 21. More broadly, the pandemic has accelerated our vision to transform point-of-care diagnostics and enable the shipment of more than 19,000 platforms through Q3 of this year, particularly For our long-term growth potential, we have a pipeline of over 30 diagnostic tests that could be performed on the platform for common health conditions, including infectious disease, cardiovascular disease, diabetes, and coagulation disorders. We currently have five products on the market. Our high-sensitivity COVID antigen test is being deployed globally to meet the urgent need to manage the COVID pandemic. In addition to our antigen, we offer a COVID antibody test which is just starting to ship now, and a COVID antigen pool test. COVID antigen pool test enables splice samples to be processed on a single test strip, offering the same lab performance as our current antigen test at higher patient throughput and lower cost. The platform also offers our INR test for monitoring patients on anticoagulation therapies such as warfarin and our deep diamond test for aiding in the diagnosis of deep vein thrombosis and pulmonary embolism. In addition, our Flask Lab solution business is serving central laboratories with its high-complexity molecular reagents. Our R&R start-complete COVID-19 assay offers groundbreaking speed and performance on open-channel PCR analyzers to enhance quality and turnaround times for central lab testing. Our long-term growth is supported by an advanced manufacturing base that allows us to supply the world with the Lumira DX platforms. with lab-comparable performance and capacity to produce the amount of testing we expect to be needed to meet demand at affordable cost. In summary, we're just beginning to drive the transformation in point-of-care testing and pursuing the $50 billion-plus global market opportunity for LumiraDx platform. With that, I'll hand things over to Dorian to go into our financial performance.